Drug Candidate Marketplace

Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. After consenting to the terms of condition and use of our services, the requested information will be provided to you.

Date Candidate Mechanism of action Indication Route Development stage Note
07/05/18 GEM023 Synthetic miniprotein for influenza virus Infuenza Preclinical Computationally designed miniprotein with demonstrated pre and post-exposure efficacy against the disease.
-Neutralizes multiple variants like H1N1 and H5N1 better than today’s standard of care while keeping immunogenicity low enough to allow chronic treatments.

Route : Inhaled
07/05/18 GEM022 Computational drug design platform for synthetic miniproteins asthma, flu and neuropathic pain etc. Discovery -High-value, high-complexity protein design by computational and high-throughput techniques.
-Mimics proven monoclonal antibodies with safer, more effective biologic alternatives.
-Designed to a specific drug target epitope with sub-nM affinity.

Route : Inhaled, Oral, Topical, IV
07/05/18 GEM021 Opioid and non-opioid analgesics with respiratory stimulant Pain Oral Preclinical (close to IND) -Combination of generic opioid/non-opioid analgesics with a generic respiratory stimulant using a regulatory approach known as the 505(b)2 submission.
-First drug introduction therapeutically equivalent to Vicodin® that prevents overdose death, deters abuse and prevents addiction.
-Low cost of goods.
06/04/18 GEM020 3rd generation immunotherapy targeting little gastrin Gastro-intestinal cancer (Pancreatic) SC Preclinical -Applied 3rd generation immunotherapy technology to little gastrin.
-In-vivo POC has been validated in non-human primates.
06/04/18 GEM019 3rd generation immunotherapy targeting HER2 HER2 overexpressing cancer (Breast) SC Preclinical -Applied 3rd generation immunotherapy technology to HER2.
-Superior efficacy to trastuzumab and pertuzumab.
-In-vivo PoC has been validated in non-human primates.
06/04/18 GEM018 3rd generation immunotherapy technology Cancer SC Discovery -Unique technology that triggers B and T cells simultaneously while activating all possible natural tumor killing mechanisms available to the immune-system.
-Tumor-directed specific activation reduces side effects to the minimum.
-Applicable on a target basis.
05/31/18 GEM009 BET inhibitor Cancer, Rheumatoid Arthritis Oral Preclinical More potent activities and lower risk of cardiovascular toxicities than competitors Contact
04/10/18 GEM008 Selective cMET inhibitor NSCLC and HCC etc. Oral Phase 2 Effective on exon 14 skipping xenograft Contact
03/26/18 GEM007 Vaccine Anthrax Oral Discovery~ Preclinical A cost-effective and safer vaccine that would produce immunity to anthrax with fewer doses Contact
03/26/18 GEM006 Bacterial NADH production inhibitor Bacterial infection Discovery~ Preclinical Inhibits synthesis of NADH in bacteria, but not in humans and expected to be used for treatment of multi-drug resistant pathogens Contact